Dipeptidyl peptidase-IV inhibition for the treatment of cardiovascular disease — recent insights focusing on angiogenesis and neovascularization

DOI Web Site Web Site PubMed 被引用文献10件 参考文献60件
  • Lei Yanna
    Department of ICU, Yanbian University Hospital
  • Hu Lina
    Department of Public Health, Guilin Medical College
  • Yang Guang
    Department of Cardiology, Yanbian University Hospital
  • Piao Limei
    Department of Cardiology, Yanbian University Hospital
  • Jin Minggen
    Department of ICU, Yanbian University Hospital
  • Cheng Xianwu
    Department of Cardiology, Yanbian University Hospital Institute of Innovation for Future Society, Nagoya University Department of Cardiovascular Internal Medicine, Kyung Hee University Hospital, Kyung Hee University

書誌事項

タイトル別名
  • Dipeptidyl Peptidase-IV Inhibition for the Treatment of Cardiovascular Disease　― Recent Insights Focusing on Angiogenesis and Neovascularization ―

この論文をさがす

抄録

<p>Dipeptidyl peptidase IV (DPP-IV) is a complex enzyme that acts as a membrane-anchored cell surface exopeptidase and transmits intracellular signals through a small intracellular tail. DPP-IV exists in human blood in a soluble form, and truncates a large number of peptide hormones, chemokines, cytokines, and growth factors in vitro and in vivo. DPP-IV has gained considerable interest as a therapeutic target, and a variety of DPP-IV inhibitors that prolong the insulinotropic effects of glucagon-like peptide-1 (GLP-1) are widely used in clinical settings as antidiabetic drugs. Indeed, DPP-IV is upregulated in proinflammatory states, including obesity and cardiovascular disease with and without diabetes mellitus. Consistent with this maladaptive role, DPP-IV inhibitors seem to exert a protective role in cardiovascular disease. In addition to their GLP-1-dependent vascular protective actions, DPP-IV inhibitors exhibit GLP-1-independent beneficial effects on angiogenesis/neovascularization via several signaling pathways (e.g., stromal cell-derived factor-1α/C-X-C chemokine receptor type-4, vascular endothelial growth factor-A/endothelial nitric oxide synthase, etc.). This review focuses on recent findings in this field, highlighting the role of DPP-IV in therapeutic angiogenesis/neovascularization in ischemic heart disease and peripheral artery disease.</p>

収録刊行物

  • Circulation Journal

    Circulation Journal 81 (6), 770-776, 2017

    一般社団法人 日本循環器学会

被引用文献 (10)*注記

もっと見る

参考文献 (60)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ